Álvaro Taus1, Laura Camacho2, Pedro Rocha3, Max Hardy-Werbin2, Lara Pijuan4, Gabriel Piquer5, Eva López6, Alba Dalmases4, Raquel Longarón5, Sergi Clavé5, Marta Salido5, Joan Albanell6, Beatriz Bellosillo5, Edurne Arriola7. 1. Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain; Universidad Autónoma de Barcelona (UAB), Barcelona, Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 2. Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 3. Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain. 4. Pathology Department, Hospital del Mar, Barcelona, Spain. 5. Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Pathology Department, Hospital del Mar, Barcelona, Spain. 6. Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 7. Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. Electronic address: earriola@parcdesalutmar.cat.
Abstract
BACKGROUND: The assessment of epidermal growth factor receptor (EGFR) mutations is crucial for the management of patients with lung adenocarcinoma. Circulating tumor DNA (ctDNA)-based assessment offers advantages over tumor as a minimally invasive method able to capture tumor heterogeneity. PATIENTS AND METHODS: Consecutive patients diagnosed with EGFR-mutant lung adenocarcinoma in tumor biopsy were included in this study. Plasma samples were obtained at different time points during the course of the disease. EGFR mutations in plasma were quantified using BEAMing (beads, emulsions, amplification, and magnetics) or digital PCR and were correlated with mutations in tumor and with radiologic response and progression. RESULTS: Two hundred twenty-one plasma samples from 33 patients were analyzed. EGFR mutations in plasma were detected in 83% of all patients and 100% of those with extrathoracic metastases. The dynamics of the EGFR mutation load predicted response in 93% and progression in 89% of cases well in advance of radiologic evaluation. Progression-free survival for patients in whom ctDNA was not detected in plasma during treatment was significantly longer than for those in whom ctDNA remained detectable (295 vs. 55 days; hazard ratio, 17.1; P < .001). CONCLUSION: The detection of EGFR mutations in ctDNA showed good correlation with that in tumor biopsy and predicted tumor response and progression in most patients. The liquid biopsy for ctDNA-based assessment of EGFR mutations is a reliable technique for diagnosis and follow-up in patients with EGFR-mutant lung adenocarcinoma in routine clinical practice.
BACKGROUND: The assessment of epidermal growth factor receptor (EGFR) mutations is crucial for the management of patients with lung adenocarcinoma. Circulating tumor DNA (ctDNA)-based assessment offers advantages over tumor as a minimally invasive method able to capture tumor heterogeneity. PATIENTS AND METHODS: Consecutive patients diagnosed with EGFR-mutant lung adenocarcinoma in tumor biopsy were included in this study. Plasma samples were obtained at different time points during the course of the disease. EGFR mutations in plasma were quantified using BEAMing (beads, emulsions, amplification, and magnetics) or digital PCR and were correlated with mutations in tumor and with radiologic response and progression. RESULTS: Two hundred twenty-one plasma samples from 33 patients were analyzed. EGFR mutations in plasma were detected in 83% of all patients and 100% of those with extrathoracic metastases. The dynamics of the EGFR mutation load predicted response in 93% and progression in 89% of cases well in advance of radiologic evaluation. Progression-free survival for patients in whom ctDNA was not detected in plasma during treatment was significantly longer than for those in whom ctDNA remained detectable (295 vs. 55 days; hazard ratio, 17.1; P < .001). CONCLUSION: The detection of EGFR mutations in ctDNA showed good correlation with that in tumor biopsy and predicted tumor response and progression in most patients. The liquid biopsy for ctDNA-based assessment of EGFR mutations is a reliable technique for diagnosis and follow-up in patients with EGFR-mutant lung adenocarcinoma in routine clinical practice.
Authors: Gloria Y F Ho; Tao Wang; Hoi-Hin Kwok; Rehana Rasul; Rita Peila; Maria Guzman; Mary S M Ip; David C L Lam Journal: Transl Lung Cancer Res Date: 2020-10
Authors: P Garrido; E Conde; J de Castro; J J Gómez-Román; E Felip; L Pijuan; D Isla; J Sanz; L Paz-Ares; F López-Ríos Journal: Clin Transl Oncol Date: 2019-10-09 Impact factor: 3.405
Authors: J Remon; R García-Campelo; E de Álava; R Vera; J L Rodríguez-Peralto; Á Rodríguez-Lescure; B Bellosillo; P Garrido; F Rojo; R Álvarez-Alegret Journal: Clin Transl Oncol Date: 2019-09-26 Impact factor: 3.405
Authors: Rafal Dziadziuszko; Tiffany Hung; Kun Wang; Voleak Choeurng; Alexander Drilon; Robert C Doebele; Fabrice Barlesi; Charlie Wu; Lucas Dennis; Joel Skoletsky; Ryan Woodhouse; Meijuan Li; Ching-Wei Chang; Brian Simmons; Todd Riehl; Timothy R Wilson Journal: Mol Oncol Date: 2022-04-22 Impact factor: 7.449
Authors: Marco Russano; Andrea Napolitano; Giulia Ribelli; Michele Iuliani; Sonia Simonetti; Fabrizio Citarella; Francesco Pantano; Emanuela Dell'Aquila; Cecilia Anesi; Nicola Silvestris; Antonella Argentiero; Antonio Giovanni Solimando; Bruno Vincenzi; Giuseppe Tonini; Daniele Santini Journal: J Exp Clin Cancer Res Date: 2020-05-27